ESR1 and neoplasm: There was no significant difference in local recurrence rates in relation to 17βHSD14 expression among systemically untreated patients (p = 0.42), but among tamoxifen treated patients with ER positive tumours, strong 17βHSD14 tumoural expression was associated with significantly better tamoxifen benefit (p = 0.022) (Fig. 5).